Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603705 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
A Phase 3 study, sponsored by Egalet.
- Completed
- Registry status
- Phase 3
- Development phase
- 281
- Enrollment target
NCT02603705: Completed Phase 3 study, sponsored by Egalet.
NCT02603705 is a Phase 3 study that has completed, run by Egalet. The registered enrollment target is 281 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02603705, a Phase 3 study, has completed, sponsored by Egalet.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 281 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
Interventions
- DRUG Oxycodone extended-release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2016-03-07 |
| Est. Completion | 2017-06-15 |
| Phase | Phase 3 |
What the finished NCT02603705 record still lists
NCT02603705 is an interventional study that assigns participants to a tested intervention. The registered 281 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 1 intervention - of which Oxycodone extended-release is the first listed.
NCT02603705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02603705 about?
NCT02603705 is a clinical study titled "Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain". The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
What is the current status of trial NCT02603705?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 281 participants. The study started on 2016-03-07. Estimated completion is 2017-06-15.
What interventions are being tested in trial NCT02603705?
The interventions under investigation include: Oxycodone extended-release (DRUG).
Who is sponsoring clinical trial NCT02603705?
This trial is sponsored by Egalet, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02603705's enrollment target sits among peer trials
281 1194th of 2000 higher than 806 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04521231 · 281 participants · Phase 1
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- NCT06190730 · 281 participants · NA
REmote Symptom COllection to improVE postopeRative Care
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI